Amniocentesis Needle Market Share, Size, Trends, Industry Analysis Report, By Type (100-150mm, Larger than 150mm, Smaller than 100mm); By Procedure; By End-Use; By Region; Segment Forecast, 2024- 2032

Amniocentesis Needle Market Share, Size, Trends, Industry Analysis Report, By Type (100-150mm, Larger than 150mm, Smaller than 100mm); By Procedure; By End-Use; By Region; Segment Forecast, 2024- 2032

The global Amniocentesis Needle market size is expected to reach USD 344.74 million by 2032, according to a new study by Polaris Market Research. The report “Amniocentesis Needle Market Share, Size, Trends, Industry Analysis Report, By Type (100-150mm, Larger than 150mm, Smaller than 100mm); By Procedure; By End-Use; By Region; Segment Forecast, 2024- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing prevalence of genetic disorders among newborns and heightened awareness of prenatal testing have led to an increasing demand for amniocentesis procedures. For instance, In 2022, MJH Life Sciences reported a global rise in the incidence of genetic diseases, citing around 300,000 babies born with sickle cell disease each year worldwide. This condition affects nearly 5% of the global population and stands as the most common genetic disorder in the U.S. This concerning trend underscores the crucial need for early detection and diagnosis of genetic abnormalities in fetuses. Consequently, the market for amniocentesis needles is expanding as a vital component of prenatal care, facilitating the identification of chromosomal and genetic disorders. This, in turn, contributes to enhanced healthcare outcomes for expecting mothers and their infants.

Furthermore, the escalating prevalence of gestational diabetes is significantly influencing market growth. This condition, impacting pregnant women, carries potentially serious consequences for both the mother and the baby, leading to an increased demand for prenatal testing and monitoring. For example, a 2022 research paper published in Frontiers in Endocrinology documented a substantial surge in the prevalence of gestational diabetes, rising from 4% in 2010 to 21% in 2020. Amniocentesis, a crucial diagnostic procedure for identifying potential fetal risks and genetic issues, has emerged as pivotal in addressing these concerns. This trend contributes to market expansion as healthcare providers strive to deliver comprehensive care to pregnant women and their unborn children.

The growing acceptance of prenatal testing stands out as a key driver for the market. Prospective parents and healthcare providers are acknowledging the significance of early and thorough prenatal assessments. This demand has been further met by advanced tests like non-invasive prenatal testing (NIPT), offering highly accurate genetic information through a simple blood test, thereby eliminating the need for invasive procedures.

During the diagnostic procedure called amniocentesis, a small quantity of amniotic fluid is extracted from the amniotic sac surrounding a developing fetus. This crucial step involves the use of an amniocentesis needle. The extracted fluid is subsequently analyzed to detect chromosomal abnormalities, genetic disorders, and other prenatal issues. Typically conducted between the 15th and 20th weeks of pregnancy, amniocentesis plays a pivotal role in providing valuable information about the health and development of the fetus.

Amniocentesis Needle Market Report Highlights

In 2023, the needle segment spanning from 100 to 150 mm claimed the largest market share, owing to its versatility and suitability for diverse medical applications such as drug administration, vaccinations, and blood sampling.

In the forecast period, the amniocentesis procedures segment held the highest revenue share, driven by the pivotal role of amniocentesis as a crucial prenatal diagnostic tool. It offers valuable insights into fetal health, genetic conditions, and chromosomal abnormalities, serving as an essential resource for expectant parents and healthcare providers.

In 2023, North America emerged as the dominant region in the global market, securing the largest market share. This dominance is attributed to a robust healthcare infrastructure, advanced prenatal care facilities, and increased awareness of the importance of prenatal testing among expectant parents. The U.S. and Canada are witnessing a rising trend among couples opting for prenatal screening to evaluate the health of their unborn babies and identify genetic conditions and chromosomal abnormalities.

The global key market players include Biopsybell Srl, Cook Medical, CooperSurgical, Integra LifeSciences, Laboratoire CCD, Medline, and RI.MOS. Srl, Rocket Medical, Smith’s Medical.

Polaris Market Research has segmented the Amniocentesis Needle market report based on type, procedure, end-use, and region:

Amniocentesis Needle, Type Outlook (Revenue - USD Million, 2019 - 2032)

100-150mm

Larger than 150mm

Smaller than 100mm

Amniocentesis Needle, Procedure Outlook (Revenue - USD Million, 2019 - 2032)

Amniocentesis

Amnioreduction

Fetal Blood Transfusion

Amnioinfusion

Cordocentesis

Amniocentesis Needle, End-Use Outlook (Revenue - USD Million, 2019 - 2032)

Hospitals

Diagnostics center

Clinics

Amniocentesis Needle, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa